Aimmune Therapeutics, Inc. (AIMT) Insider Sells $61,519.84 in Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $37.33, for a total value of $61,519.84. Following the transaction, the insider now owns 1,648 shares in the company, valued at approximately $61,519.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aimmune Therapeutics, Inc. (AIMT) opened at $39.00 on Thursday. Aimmune Therapeutics, Inc. has a 1-year low of $15.97 and a 1-year high of $40.00. The firm has a market capitalization of $1,980.00 and a PE ratio of -16.67.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics, Inc. will post -2.51 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares in the last quarter. Legal & General Group Plc raised its position in Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC raised its position in Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the last quarter. Franklin Street Advisors Inc. NC raised its position in Aimmune Therapeutics by 43.8% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 16,420 shares of the biotechnology company’s stock valued at $621,000 after buying an additional 5,000 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Aimmune Therapeutics in the 2nd quarter valued at approximately $360,000. Institutional investors and hedge funds own 73.34% of the company’s stock.

AIMT has been the topic of a number of recent analyst reports. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Roth Capital began coverage on Aimmune Therapeutics in a report on Monday, November 20th. They set a “buy” rating and a $60.00 price objective on the stock. Piper Jaffray Companies lifted their price objective on Aimmune Therapeutics from $38.00 to $60.00 and gave the company an “overweight” rating in a report on Tuesday, December 5th. Finally, Wedbush reiterated an “outperform” rating and set a $70.00 price objective (up previously from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $55.43.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/aimmune-therapeutics-inc-aimt-insider-sells-61519-84-in-stock.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply